Latest & greatest articles for lung cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for lung cancer

81. Pembrolizumab (Keytruda) - metastatic non-squamous non-small cell lung carcinoma (NSCLC)

www.scottishmedicines.org.uk 2 Indication In combination with pemetrexed and platinum chemotherapy, for the first-line treatment of metastatic non-squamous non-small cell lung carcinoma (NSCLC) in adults whose tumours have no EGFR or ALK positive mutations. 1, 2 Dosing Information Pembrolizumab 200mg administered as an intravenous infusion over 30 minutes every 3 weeks. Patients should be treated with pembrolizumab until disease progression or unacceptable toxicity. Atypical responses (i.e. an initial transient increase (...) is summarised as follows: ADVICE: following a full submission assessed under the end of life process pembrolizumab (Keytruda ® ) is not recommended for use within NHSScotland. Indication under review: in combination with pemetrexed and platinum chemotherapy, for the first-line treatment of metastatic non-squamous non-small cell lung carcinoma (NSCLC) in adults whose tumours have no EGFR or ALK positive mutations. The addition of pembrolizumab to pemetrexed and platinum chemotherapy significantly improved

2019 Scottish Medicines Consortium

82. Persisting new nodules in incidence rounds of the NELSON CT lung cancer screening study Full Text available with Trip Pro

Persisting new nodules in incidence rounds of the NELSON CT lung cancer screening study The US guidelines recommend low-dose CT (LDCT) lung cancer screening for high-risk individuals. New solid nodules after baseline screening are common and have a high lung cancer probability. Currently, no evidence exists concerning the risk stratification of non-resolving new solid nodules at first LDCT screening after initial detection.In the Dutch-Belgian Randomized Lung Cancer Screening (NELSON) trial (...) nodules were resolving, leaving 356 (52%) participants with a non-resolving new solid nodule, of whom 25 (7%) were diagnosed with lung cancer. At first screening after initial detection, volume doubling time (VDT), volume, and VDT combined with a predefined ≥200 mm3 volume cut-off had high discrimination for lung cancer (VDT, area under the curve (AUC): 0.913; volume, AUC: 0.875; VDT and ≥200 mm3 combination, AUC: 0.939). Classifying a new solid nodule with either ≤590 days VDT or ≥200 mm3 volume

2019 EvidenceUpdates

83. Short-Term Readmissions After Open, Thoracoscopic, and Robotic Lobectomy for Lung Cancer Based on the Nationwide Readmissions Database (Abstract)

Short-Term Readmissions After Open, Thoracoscopic, and Robotic Lobectomy for Lung Cancer Based on the Nationwide Readmissions Database Readmission after surgery is an established surrogate indicator of quality of care. We aimed to compare short-term readmission rates and patient outcomes between open, video-assisted thoracoscopic (VATS), and robotic lobectomies in the Nationwide Readmissions Database (NRD).Adults who underwent open, VATS, or robotic lobectomy for lung cancer from 2010 to 2014 (...) were evaluated. Propensity-matched analysis was used to assess differences in readmission characteristics, GDP-adjusted cost, and mortality.Of the 129,539 lobectomies for lung cancer, 74,493 (57.5%) were open, 48,185 (37.2%) VATS, and 6861 (5.3%) robotic. Open surgery was associated with significantly higher readmission rate (10.5 vs 9.3%, p < 0.001), mortality (2 vs 1.2%, p < 0.001), index hospitalization cost [$21,846 (16,158-31,034) vs $20,779 (15,619-27,920), p < 0.001], and length of stay [6

2019 EvidenceUpdates

84. Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study Full Text available with Trip Pro

Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study Veliparib, a poly (ADP ribose) polymerase inhibitor, potentiated standard chemotherapy against small-cell lung cancer (SCLC) in preclinical studies. We evaluated the combination of veliparib with cisplatin and etoposide (CE; CE+V) doublet in untreated, extensive-stage SCLC (ES-SCLC).Patients with ES-SCLC, stratified by sex and serum

2019 EvidenceUpdates

85. Circulating high sensitivity C reactive protein concentrations and risk of lung cancer: nested case-control study within Lung Cancer Cohort Consortium. Full Text available with Trip Pro

<0.01 for interaction). This association was strong and consistent across all histological subtypes, except for adenocarcinoma, which was not strongly associated with hsCRP concentration regardless of smoking status (odds ratio for adenocarcinoma overall 0.97, 95% confidence interval 0.94 to 1.01). The association between circulating hsCRP concentration and the risk of lung cancer was strongest in the first two years of follow-up for former and current smokers. Including hsCRP concentration (...) in a risk model, in addition to smoking based variables, did not improve risk discrimination overall, but slightly improved discrimination for cancers diagnosed in the first two years of follow-up.Former and current smokers with higher circulating hsCRP concentrations had a higher risk of lung cancer overall. Circulating hsCRP concentration was not associated with the risk of lung adenocarcinoma. Circulating hsCRP concentration could be a prediagnostic marker of lung cancer rather than a causal risk

2019 BMJ

86. Lobectomy versus stereotactic ablative radiotherapy for medically operable patients with stage IA non-small cell lung cancer: A virtual randomized phase III trial stratified by age. Full Text available with Trip Pro

Lobectomy versus stereotactic ablative radiotherapy for medically operable patients with stage IA non-small cell lung cancer: A virtual randomized phase III trial stratified by age. Although the choice between stereotactic ablative radiotherapy (SABR) and lobectomy for early-stage non-small cell lung cancer (NSCLC) has been debated for years, the two procedures have not yet been directly compared in a randomized trial. We conducted a virtual randomized phase III trial stratified by age (...) no statistically significant difference in the expected overall survival in stage IA NSCLC patients who were older than 75 years and had undergone SABR or lobectomy.© 2019 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

2019 Thoracic cancer Controlled trial quality: uncertain

87. A Model-Based Cost-Effectiveness Analysis of an Exercise Program for Lung Cancer Survivors Following Curative-Intent Treatment. Full Text available with Trip Pro

A Model-Based Cost-Effectiveness Analysis of an Exercise Program for Lung Cancer Survivors Following Curative-Intent Treatment. The cost-effectiveness of exercise interventions in lung cancer survivors is unknown. We performed a model-based cost-effectiveness analysis of an exercise intervention in lung cancer survivors.We used Markov modeling to simulate the impact of the Lifestyle Interventions and Independence for Elders (LIFE) exercise intervention compared to usual care for stage I-IIIA (...) lung cancer survivors following curative-intent treatment. We calculated and considered incremental cost-effectiveness ratios (ICERs) <$100,000/quality-adjusted life-year (QALY) as cost-effective and assessed model uncertainty using sensitivity analyses.The base-case model showed that the LIFE exercise program would increase overall cost by $4,740 and effectiveness by 0.06 QALYs compared to usual care and have an ICER of $79,504/QALY. The model was most sensitive to the cost of the exercise program

2019 American journal of physical medicine & rehabilitation Controlled trial quality: uncertain

88. Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER-0303. Full Text available with Trip Pro

Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER-0303. Anlotinib is an oral tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor, fibroblast growth factor receptor, platelet-derived growth factor receptor, and stem cell factor receptor (c-Kit). In the phase III ALTER-0303 trial (Clinical Trial Registry ID: NCT 02388919), anlotinib significantly improved overall survival versus placebo in advanced (...) non-small cell lung cancer patients who had received at least two previous chemotherapy and epidermal growth factor receptor/anaplastic lymphoma kinase targeted therapy regimens. This study summarized adverse event management in this trial.Patients were randomized (2:1) to anlotinib or placebo up to progression or intolerable toxicity. Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 and managed by investigators. Key

2019 Thoracic cancer Controlled trial quality: uncertain

89. Alectinib (Alecensa) for the treatment of patients with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)

Alectinib (Alecensa) for the treatment of patients with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) 1 Cost-effectiveness of alectinib (Alecensa®) for the first line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung carcinoma (NSCLC) The NCPE has issued a recommendation regarding the cost-effectiveness of alectinib (Alecensa®). Following assessment of the applicant’s submission, the NCPE recommends (...) lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). At the same time, they also converted the conditional marketing authorisation to a standard marketing authorisation for the crizotinib failure indication (2L) which had been approved in the EU since February 2017. In April 2018, Roche Products (Ireland) Ltd submitted a dossier examining the cost-effectiveness of alectinib for the first-line treatment of ALK-positive advanced NSCLC. The authorised dose for this indication

2019 Pediatric Endocrine Society

90. Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer

within the Cancer Drugs Fund, as an option for untreated, metastatic, non-squamous non-small-cell lung cancer (NSCLC) in adults whose tumours have no epidermal growth factor receptor (EGFR)- or anaplastic lymphoma kinase (ALK)-positive mutations. It is only recommended if: pembrolizumab is stopped at 2 years of uninterrupted treatment or earlier if disease progresses and the company provides pembrolizumab according to the managed access agreement. 1.2 This recommendation is not intended to affect (...) non-squamous non-small-cell lung carcinoma (NSCLC) in adults whose tumours have no epidermal growth factor receptor or anaplastic lymphoma kinase-positive tumour mutations' . Dosage in Dosage in the the mark marketing eting authorisation authorisation 200 mg every 3 weeks by intravenous infusion. The summary of product characteristics recommends treatment with pembrolizumab until disease progression or unacceptable toxicity. Price Price £1,315.00 per 50 mg vial (excluding VAT; British national

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

91. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic non-small cell lung cancer

annually, exceeding those from any other malignancy [1]. Lung cancer is the most common cause of cancer death in men and the second leading cause of cancer death in women, worldwide. It is the commonest cancer in Asia and is the leading cause of death in Southern, Eastern and South Eastern Asia [2]. Fifty-one percent of the world’s lung cancer cases occur in Asia [3], and 21% of cancer deaths in Asia are due to lung can- cer [4]. The number of cases and the crude and standardised inci- dence rates (...) who have never smoked being especially marked in Asian countries [17]. A recent Korean study of 5456 cases of lung cancer in a community cancer centre showed the proportion of cases in never smokers to have increased from 19.4% between 2004 and 2008 to 25.4% be- tween 2009 and 2012 [18]. Epidemiological data have resulted in ‘non-smoking-associ- ated lung cancer’ being considered a distinct disease entity, where speci?c molecular and genetic differences have been identi?ed between the lung cancers

2019 European Society for Medical Oncology

92. ASTRO Guideline on Palliative Radiation Therapy for Non-small Cell Lung Cancer (NSCLC) - Update Full Text available with Trip Pro

ASTRO Guideline on Palliative Radiation Therapy for Non-small Cell Lung Cancer (NSCLC) - Update Palliative thoracic radiation therapy for non-small cell lung cancer: 2018 Update of an American Society for Radiation Oncology (ASTRO) Evidence-Based Guideline - Practical Radiation Oncology Email/Username: Password: Remember me Search Terms Search within Search Share this page: Volume 8, Issue 4, Pages 245–250 Palliative thoracic radiation therapy for non-small cell lung cancer: 2018 Update (...) Accepted: February 19, 2018 ; Received: February 6, 2018 ; Abstract Purpose To revise the recommendation on the use of concurrent chemotherapy (CC) with palliative thoracic external beam radiation therapy (EBRT) made in the original 2011 American Society for Radiation Oncology guideline on palliative thoracic radiation for lung cancer. Methods and materials Based on a systematic PubMed search showing new evidence for this key question, the task force felt an update was merited. Guideline

2019 American Society for Radiation Oncology

93. Relationship between volume of services and quality of treatment outcome for lung cancer - rapid report

lung cancers are epithelial tumours that develop from squamous or glandular epithelium (adenocarcinoma) [9]. Lung carcinoma is also referred to as bronchial carcinoma since this malignant tumour arises from the bronchial epithelium [10, 11]. It is classified into the following main histological types [12]: ? Small cell lung cancer (SCLC; approx. 15%) ? Non-small cell lung cancer (NSCLC; approx. 85%): ? squamous cell carcinoma: spindle cell variant (40%) Extract of rapid report V18-03 Version 1.0 (...) malignant tumours in the lung Malignant lymphomas and sarcomas are cancerous tumours that can arise as primary thoracic tumours or as lung metastases [14]. Metastases to the lung often also develop in connection with carcinomas of the colon, rectum, kidney, breast, prostate, and oropharynx [15]. Diffuse malignant pleural mesothelioma originates in the mesothelial or submesothelial cells of the pleura, peritoneum, or pericardium. More than 80% of mesotheliomas originate in the pleura. Mesothelioma

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

94. Osimertinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V

Gibbert ? Thomas Kaiser ? Petra Kohlepp ? Ulrike Lampert ? Katrin Nink Keywords: osimertinib, carcinoma – non-small-cell lung, benefit assessment, NCT02296125 Extract of dossier assessment A18-45 Version 1.0 Osimertinib (non-small cell lung cancer) 11 October 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - 1 - Executive summary of the benefit assessment Background In accordance with §35a Social Code Book (SBG) V, the Federal Joint Committee (G-BA) commissioned the Institute (...) Osimertinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of the executive summary of the dossier assessment Osimertinib (nicht kleinzelliges Lungenkarzinom) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 11 October 2018). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English- language readers. However, solely the German original text is absolutely

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

95. Durvalumab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V

-small cell lung cancer (NSCLC) whose tumours express programmed cell death ligand-1 (PD-L1) on = 1% of tumour cells and whose disease did not progress following platinum-based chemoradiotherapy. Table 2 presents the research question of the benefit assessment and the ACT specified by the G-BA. Table 2 2 : Research question of the benefit assessment of durvalumab Indication ACT a Adults with locally advanced, inoperable NSCLC whose tumours express PD-L1 on = 1% of tumour cells and whose disease has (...) Durvalumab (locally advanced, unresectable NSCLC) 10 January 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - 2 - Included were adult patients with locally advanced, inoperable NSCLC (stage III according to the International Association for the Study of Lung Cancer [IASLC] Version 7) with no disease progression following definitive, combined, platinum-based chemoradiotherapy. In the study, 713 patients were randomized, 476 to the intervention arm and 237 to the comparator arm. In both

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

96. Pembrolizumab (non-squamous non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V

cancer (MK-3475- 021/KEYNOTE-021): study results [online]. In: ClinicalTrials.gov. 30.01.2019 [Accessed: 16.05.2019]. URL: https://clinicaltrials.gov/ct2/show/results/NCT02039674. Merck Sharp Dohme. A phase 1/2 study of MK-3475 (SCH900475) in combination with chemotherapy or immunotherapy in patients with locally advanced or metastatic non-small cell lung carcinoma: study P021V03MK3475; clinical study report [unpublished]. 2018. Merck Sharp Dohme. Pembrolizumab KEYNOTE 021G trial platinum therapy (...) Pembrolizumab (non-squamous non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Pembrolizumab (nicht plattenepitheliales NSCLC, Kombinationschemotherapie) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 27 June 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

97. Pembrolizumab (squamous non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V

: hazard ratio; n: number of patients with at least one event; N: number of analysed patients; NA: not achieved; QLQ-C30: Quality of Life Questionnaire-Core 30; QLQ-LC13: Quality of Life Questionnaire-Lung Cancer 13; RCT: randomized controlled trial; SAE: serious adverse event; TPS: Tumour Proportion Score; VAS: visual analogue scale; vs.: versus Based on the available data, at most indications, e.g. of an added benefit, can be derived for the outcomes “symptoms” (measured with the EORTC QLQ-C30 (...) Pembrolizumab (squamous non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Pembrolizumab (plattenepitheliales NSCLC, Kombinationschemotherapie) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 27 June 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

98. Delivering best practice lung cancer care - a guide for health professionals

, investigate and refer patients with symptoms that may be lung cancer according to best practice evidence. 32 ` ` Services should have clearly documented pathways and facilitate timely and streamlined referral of patients into the specialist lung cancer team for diagnosis, staging and treatment in line with the national Optimal Care Pathway. 30,31 ` ` Clearly defined evidence-based treatment pathways for patients with lung cancer should be developed according to disease stage. ` ` All patients (...) . 46. Freeman RK, Van Woerkom JM, Vyverberg A, Ascioti AJ. The effect of a multidisciplinary thoracic malignancy conference on the treatment of patients with lung cancer. European Journal of Cardio-Thoracic Surgery. 2010;38(1):1-5. 47. Pillay B, Wootten AC, Crowe H, et al. The impact of multidisciplinary team meetings on patient assessment, management and outcomes in oncology settings: A systematic review of the literature. Cancer Treatment Reviews. 2016;42:56-72. 48. Boxer MM, Vinod SK, Shafiq J

2018 Cancer Australia

99. Lorlatinib (Lorbrena) - To treat patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer

Lorlatinib (Lorbrena) - To treat patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer Drug Approval Package: LORBRENA (lorlatinib) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: LORBRENA (lorlatinib) Company: Pfizer, Inc. Application Number: 210868 Approval Date: 11/02/2018 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter

2018 FDA - Drug Approval Package

100. Brigatinib (Alunbrig) - non-small cell lung cancer (NSCLC)

Brigatinib (Alunbrig) - non-small cell lung cancer (NSCLC) 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. EMA/674777/2018 EMEA/H/C/004248 Alunbrig (brigatinib) An overview of Alunbrig and why it is authorised in the EU What (...) is Alunbrig and what is it used for? Alunbrig is a cancer medicine that is used to treat adults with a type of lung cancer called non-small cell lung cancer (NSCLC) who have been treated before with a cancer medicine called crizotinib. Alunbrig is used on its own and only if the NSCLC is ‘ALK-positive’, which means that the cancer cells have certain changes affecting the gene that makes a protein called ALK (anaplastic lymphoma kinase). Alunbrig contains the active substance brigatinib. How is Alunbrig

2018 European Medicines Agency - EPARs